Seeking Alpha

Analysts continue to beat the drum for Pfizer PFE witnessed by JPMorgan reiterating an...

Analysts continue to beat the drum for Pfizer PFE witnessed by JPMorgan reiterating an Overweight rating on shares with a $25 price target, following Goldman Sachs adding the firm to its Conviction Buy List yesterday. Shares are down 1.4%, standing as the leader for Dow components on the day.
Comments (5)
  • They must have destroyed that drum by now. Its been beaten up over the last decade on and off. I do not see where there is organic growth here, its all by acquisition. Their dividend is a good reward for someone looking for income, but if you want to be defensive, corporate bonds and preferred stocks are worth a look. You can actually get a decent return on them for income. PFE's stock price is stuck in the mud. I guess I do not understand why you would put money in PFE.
    10 Aug 2011, 12:26 PM Reply Like
  • If everybody is buying, who is selling?
    10 Aug 2011, 12:40 PM Reply Like
  • If everybody is selling, who is buying?
    10 Aug 2011, 01:25 PM Reply Like
  • Searching for donJuan
    10 Aug 2011, 12:41 PM Reply Like
  • Yah I don't know why anyone would want to invest in a drug company that has decided to cut back so sharply on research and development in favor of short term profits. Maybe Pfizer thinks stock buybacks will somehow cause the Tooth Fairy to leave new ready-to-test drugs under its pillow some night.
    10 Aug 2011, 12:47 PM Reply Like
DJIA (DIA) S&P 500 (SPY)